These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11446269)

  • 1. Valsartan and the kidney: review of preclinical and clinical data.
    Ruilope LM
    Adv Ther; 2001; 18(2):57-66. PubMed ID: 11446269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valsartan and the kidney: present and future.
    Mann JF
    J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S37-40; discussion S41-3. PubMed ID: 10028953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
    Burrell LM; Johnston CI
    Drugs Aging; 1997 Jun; 10(6):421-34. PubMed ID: 9205848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
    Lassila M; Finckenberg P; Pere AK; Krogerus L; Ahonen J; Vapaatalo H; Nurminen ML
    Br J Pharmacol; 2000 Jul; 130(6):1339-47. PubMed ID: 10903974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Coca A; Giner V
    Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
    Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
    Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
    Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
    Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan.
    Locatelli F; Palmer BF; Kashihara N; Ecder T
    Curr Med Res Opin; 2009 Dec; 25(12):2933-49. PubMed ID: 19835466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension.
    Mahmud A; Feely J
    J Hum Hypertens; 2000 Sep; 14(9):541-6. PubMed ID: 10980584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
    Yarows SA
    Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):19-33. PubMed ID: 20030022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P; Andersen S; Jensen BR; Parving HH
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
    Martin J; Krum H
    Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin II receptor blockers: current status and future prospects].
    Corvol P; Plouin PF
    Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
    Davis BJ; Cao Z; de Gasparo M; Kawachi H; Cooper ME; Allen TJ
    J Hypertens; 2003 Jan; 21(1):209-16. PubMed ID: 12544453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
    Ramahi TM
    Postgrad Med; 2001 Apr; 109(4):115-22; quiz 9. PubMed ID: 11317462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-II receptor antagonists: their place in therapy.
    Kirk JK
    Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.